Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages 4333-4338

  Peterson, Douglas E ^a   Barker, Nicholas P ^a   Akhmadullina, Lilia I ^a   Rodionova, Irina ^a   Sherman, Nailya Z ^a   Davidenko, Irina S ^a   Rakovskaya, Galina N ^a   Gotovkin, Eugeny A ^a   Shinkarev, Sergey A ^a   Kopp, Mikhail V ^a   Kulikov, Eugeny P ^a   Moiseyenko, Vladimir M ^a   Gertner, Joseph M ^a   Firsov, Igor ^a   Tuleneva, Tamara ^a   Yarosh, Alexander ^a   Woon, Chee Wai ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; INTESTINAL TREFOIL FACTOR; PLACEBO; RECOMBINANT HUMAN INTESTINAL TREFOIL FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PEPTIDE; RECOMBINANT PROTEIN; TREFOIL FACTOR;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MORBIDITY; MOUTH PAIN; MUCOSA INFLAMMATION; ORAL MUCOSITIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; AGED; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; GENETICS; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; STOMATITIS; TREATMENT OUTCOME;

ABDOMINAL PAIN; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; FLUOROURACIL; HEADACHE; HUMANS; HYPERTENSION; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PEPTIDES; RECOMBINANT PROTEINS; STOMATITIS; TREATMENT OUTCOME;

EID: 70349317269     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.2381     Document Type: Article

References (40)

1. Keefe DM, Schubert MM, Elting LS, et al: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820-831, 2007
2. Elting LS, Keefe DM, Sonis ST, et al: Patientreported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer 113:2704-2713, 2008
3. Lalla RV, Sonis ST, Peterson DE: Management of oral mucositis in patients who have cancer. Dent Clin North Am 52:61-77, viii, 2008
4. Sonis ST, Elting LS, Keefe D, et al: Perspectives on cancer therapy-induced mucosal injury. Cancer 100:1995-2025, 2004 (suppl 9)
5. Cella D, Pulliam J, Fuchs H, et al: Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 98:406-412, 2003
6. Harris DJ: Cancer treatment-induced mucositis pain: Strategies for assessment and management. Ther Clin Risk Manag 2:251-258, 2006
7. Epstein JB, Robertson M, Emerton S, et al: Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 23:389-398, 2001
8. Ruescher TJ, Sodeifi A, Scrivani SJ, et al: The impact of mucositis on α-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82:2275-2281, 1998
9. Elting LS, Cooksley C, Chambers M, et al: The burdens of cancer therapy: Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531-1539, 2003
10. Beck PL, Wong JF, Li Y, et al: Chemotherapyand radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology 126:796-808, 2004
11. Podolsky DK, Lynch-Devaney K, Stow JL, et al: Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem 268:6694-6702, 1993
12. Poulsom R, Wright NA: Trefoil peptides: A newly recognized family of epithelial mucin-associated molecules. Am J Physiol 265:G205-G213, 1993
13. Thim L, Madsen F, Poulsen SS: Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest 32:519-527, 2002
14. Kindon H, Pothoulakis C, Thim L, et al: Trefoil peptide protection of intestinal epithelial barrier function: Cooperative interaction with mucin glycoprotein. Gastroenterology 109:516-523, 1995
15. Kjellev S, Nexo E, Thim L, et al: Systemically administered trefoil factors are secreted into the gastric lumen and increase the viscosity of gastric contents. Br J Pharmacol 149:92-99, 2006
16. Kinoshita K, Taupin DR, Itoh H, et al: Distinct pathways of cell migration and antiapoptotic response to epithelial injury: Structure-function analysis of human intestinal trefoil factor. Mol Cell Biol 20:4680-4690, 2000
17. Liu D, el-Haririy I, Karayiannakis AJ, et al: Phosphorylation of β-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 77:557-563, 1997
18. Kanai M, Mullen C, Podolsky DK: Intestinal trefoil factor induces inactivation of extracellular signal-regulated protein kinase in intestinal epithelial cells. Proc Natl Acad Sci U S A 95:178-182, 1998
19. Taupin DR, Kinoshita K, Podolsky DK: Intestinal trefoil factor confers colonic epithelial resistant to apoptosis. Proc Natl Acad Sci U S A 97:799-804, 2000
20. Chen YH, Lu Y, De Plaen IG, et al: Transcription factor NF-kappaB signals anti-anoikic function of trefoil factor 3 on intestinal epithelial cells. Biochem Biophys Res Comm 274:576-582, 2000
21. Tan XD, Chen YH, Liu QP, et al: Prostanoids mediate the protective effect of trefoil factor 3 in oxidant-induced intestinal epithelial cell injury: Role of cyclooxygenase-2. J Cell Sci 113:2149-2155, 2000
22. Andoh A, Kinoshita K, Rosenberg I, et al: Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells. J Immunol 167:3887-3893, 2001
23. Dignass A, Lynch-Devaney K, Kindon H, et al: Trefoil peptides promote epithelial migration through a transforming growth factor β-independent pathway. J Clin Invest 94:376-383, 1994
24. Dürer U, Hartig R, Bang S, et al: TFF3 and EGF induce different migration patterns of intestinal epithelial cells in vitro and trigger increased internalization of E-cadhedrin. Cell Physiol Biochem 20:329-346, 2007
25. Mashimo H, Wu DC, Podolsky DK, et al: Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274:262-265, 1996
26. Babyatsky MW, DeBeaumont M, Thim L, et al: Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 110:489-497, 1996
27. Poulsen SS, Kissow H, Hare K, et al: Luminal and parenteral TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat. Regul Pept 126:163-171, 2005
28. Vandenbroucke K, Hans W, van Huysse J, et al: Active delivery of trefoil factors by genetically modified Lactocossus lactis prevents and heals acute colitis in mice. Gastroenterology 127:502-513, 2004
29. Zhang BH, Yu HG, Sheng Z-X, et al: The therapeutic effect of recombinant human trefoil factor 3 on hypoxia-induced necrotizing enterocolitis in immature rat. Regul Pept 116:53-60, 2003
30. Podolsky DK: Mechanisms of regulatory peptide action in the gastrointestinal tract: Trefoil peptides. J Gastroenterol 35:69-74, 2000 (suppl XII)
31. Sonis ST, Eilers JP, Epstein JB, et al: Validation of new scoring system for assessment of clinical trial research of oral mucositis by radiation or chemotherapy. Cancer 85:2103-2113, 1999
32. Hauser F, Poulsom R, Chinery R, et al: HP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. Proc Natl Acad Sci U S A 90:6961-6965, 1993
33. Peterson DE, Jones JR, Petit II RG: Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 109:322-331, 2007
34. Johnson WF, DiPalma CR, Ziegler TR, et al: Keratinocyte growth factor enhances early gut adaptation in a rat model of short bowel syndrome. Vet Surg 29:17-27, 2000
35. Iwakiri D, Podolsky DK: Keratinocyte growth factor promotes goblet cell differentiation through regulation of goblet cell silencer inhibitor. Gastroenterology 120:1372-1380, 2001
36. Hi T cell transfer mouse models of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 282:G690-G701, 2002
37. Rosen LS, Abdi E, Davis ID, et al: Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 24: 5194-5200, 2006
38. Storesund T, Hayashi K, Kolltvelt KM, et al: Salivary trefoil factor 3 enhances migration of oral keratinocytes. Eur J Oral Sci 116:135-140, 2008
39. Marchbank T, Cox HM, Goodlad RA, et al: Effect of ectopic expression of rat trefoil factor family 3 (intestinal trefoil factor) in the jejunum of transgenic mice. J Biol Chem 276:24088-24096, 2001
40. John R, El-Rouby NM, Tomasetto C, et al: Expression of TFF3 during multistep colon carcinogenesis. Histol Histopathol 22:743-751, 2007